-+ 0.00%
-+ 0.00%
-+ 0.00%

Impact Therapeutics licenses senaparib rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 million

PUBT·08/03/2026 05:58:10
Listen to the news
Impact Therapeutics licenses senaparib rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 million
  • Impact Therapeutics signed an exclusive license deal with Pharmanovia for senaparib rights across Europe, the Middle East, North Africa, Australia, New Zealand.
  • Agreement covers manufacturing, development, commercialization for first-line maintenance monotherapy in advanced high-grade epithelial ovarian, fallopian tube, primary peritoneal cancers.
  • Impact eligible for up to EUR 423.5 million in upfront and milestone payments, tied to regulatory events and revenue thresholds.
  • Deal includes tiered royalties up to about 25% of net product sales.
  • EMA accepted the European marketing application in August 2025; a decision is expected in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608030156PR_NEWS_EUPR__FR_FR16632) on August 03, 2026, and is solely responsible for the information contained therein.